LP
CAI

Longaeva Partners’s Caris Life Sciences CAI Stock Holding History

Longaeva Partners’s Portfolio CAI Stock Details CAI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-1,509,745
Closed -$40.7M – 260
2025
Q4 		$40.7M Buy
1,509,745
+223,777
+17% +$6.3M 3.42% 4
2025
Q3 		$38.9M Sell
1,285,968
-173,777
-12% -$5.54M 5.61% 5
2025
Q2 		$39M Buy
+1,459,745
New +$39.3M 7.96% 2

Other funds holding CAI

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
JHWEPV
J. H. Whitney Equity Partners VI New Canaan, Connecticut $201M AUM
SSP
Sixth Street Partners Dallas, Texas $579M AUM 2.46% 1-Year Est. Return
Coatue Management
Coatue Management New York $48.6B AUM 94.27% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $2.7B AUM 88.53% 1-Year Est. Return
PC
PointState Capital New York $7.82B AUM 43.51% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Longaeva Partners's CAI Position: Q1 2026 in Review

Longaeva Partners sold out of Caris Life Sciences (CAI) in Q1 2026, closing a stake of 1,509,745 shares — an estimated $40.7M sold.

Longaeva Partners first reported a position in CAI in Q2 2025 and held it in 3 quarters. The position peaked at $40.7M in Q4 2025. 202 funds tracked by Wall St. Rank hold CAI as of Q1 2026.

  • Longaeva Partners reported no remaining Caris Life Sciences position as of Q1 2026 after selling out during the quarter.
  • Longaeva Partners sold 1,509,745 Caris Life Sciences shares in Q1 2026, an estimated $40.7M.
  • Longaeva Partners first reported a position in Caris Life Sciences in Q2 2025 and held it in 3 quarters.
  • Longaeva Partners's Caris Life Sciences position peaked at $40.7M in Q4 2025.
  • 202 funds tracked by Wall St. Rank held Caris Life Sciences as of Q1 2026.

Based on Longaeva Partners's 13F filing for Q1 2026, filed 15 May 2026.